Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ideate-Pantumor02
2023-509632-26-00Phase 2Authorised
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 18
01
Overview
Phase 2, open-label, single-arm trial of ifinatamab deruxtecan in Nonhematologic neoplasms, endometrial cancer (EC), head and neck squamous cell carcinoma (HNSCC) and 12 more, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Objective response rate and Dose-limiting toxicities and treatment-emergent adverse events. Planned start Dec 2024; status: authorised.
02
Drugs
ifinatamab deruxtecan
03
Conditions
Nonhematologic neoplasmsendometrial cancer (EC)head and neck squamous cell carcinoma (HNSCC)pancreatic adenocarcinoma (PDAC)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2023-509632-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509632-26-00.